Spectranetics Catheter Sales Benefiting From RotaLink Recall
This article was originally published in The Gray Sheet
Executive Summary
Spectranetics placed 16 atherectomy lasers and saw sales of disposable coronary angioplasty catheters more than double in the third quarter, largely at the expense of Boston Scientific's RotaLink Plus atherectomy system, the company reported Nov. 30 at the BancBoston Robertson Stephens annual health care conference in New York City.
You may also be interested in...
Boston Scientific's Rotablator Anticipated To Generate $15 mil. In Q4 Sales
A limited reintroduction of Boston Scientific's original Rotablator rotational atherectomy device later this month is anticipated to generate $15 mil. in sales for the firm in the fourth quarter.
Baxter v. Spectranetics
Patent infringement suit is filed by Baxter in Delaware district court alleging that Spectranetics' CVX-300 excimer laser system infringes three patents licensed by Baxter from Lasersight (patent number 4,784,135), Acculase (4,891,818), and the U.S. Department of Energy/Argonne National Laboratory (4,686,979). The patents cover cardiovascular and vascular uses of excimer laser technology. Spectranetics' CVX-300 is approved for laser angioplasty in coronary arteries. The company also is planning trials in October to use the system to treat in-stent restenosis
Boston Scientific Pursues Dual Strategy In Addressing RotaLink Recall
Boston Scientific may opt to restart production of its original Rotablator atherectomy system following the Aug. 6 recall of the next-generation RotaLink Plus, the company reported at a same-day teleconference.